Despite significant advances in monoclonal antibodies (Mabs) technology over the last two decades, technology to develop natural occurring and fully human therapeutic Mabs from patients without known antigens is still...Despite significant advances in monoclonal antibodies (Mabs) technology over the last two decades, technology to develop natural occurring and fully human therapeutic Mabs from patients without known antigens is still in its infancy. Human myeloma cell lines have been very difficult to derive. Attempts in numerous laboratories to use those cells for the production of human monoclonal antibodies have failed despite early reports. A human myeloma cell line that is suitable for the generation of human monoclonal antibodies (Proceedings of the National Academy of Sciences USA 98:1799-1804) was developed by Dr. Karpas. Since 1975 researchers across the world have been trying to replicate the process with human cells.展开更多
文摘Despite significant advances in monoclonal antibodies (Mabs) technology over the last two decades, technology to develop natural occurring and fully human therapeutic Mabs from patients without known antigens is still in its infancy. Human myeloma cell lines have been very difficult to derive. Attempts in numerous laboratories to use those cells for the production of human monoclonal antibodies have failed despite early reports. A human myeloma cell line that is suitable for the generation of human monoclonal antibodies (Proceedings of the National Academy of Sciences USA 98:1799-1804) was developed by Dr. Karpas. Since 1975 researchers across the world have been trying to replicate the process with human cells.
